GB201412010D0 - Treatment of hypertransaminasemia - Google Patents

Treatment of hypertransaminasemia

Info

Publication number: GB201412010D0
Authority: GB; United Kingdom
Prior art keywords: hypertransaminasemia; treatment
Prior art date: 2014-07-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

GBGB1412010.9A

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Summit Therapeutics Ltd

Original Assignee

Summit Corp PLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-07-04

Filing date

2014-07-04

Publication date

2014-08-20

2014-07-04 Application filed by Summit Corp PLC filed Critical Summit Corp PLC

2014-07-04 Priority to GBGB1412010.9A priority Critical patent/GB201412010D0/en

2014-08-20 Publication of GB201412010D0 publication Critical patent/GB201412010D0/en

2015-07-02 Priority to PCT/GB2015/051943 priority patent/WO2016001682A1/en

Status Ceased legal-status Critical Current

Links

206010068237 Hypertransaminasaemia Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

GBGB1412010.9A 2014-07-04 2014-07-04 Treatment of hypertransaminasemia Ceased GB201412010D0 (en)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
GBGB1412010.9A GB201412010D0 (en)	2014-07-04	2014-07-04	Treatment of hypertransaminasemia
PCT/GB2015/051943 WO2016001682A1 (en)	2014-07-04	2015-07-02	Treatment of hypertransaminasemia

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB1412010.9A GB201412010D0 (en)	2014-07-04	2014-07-04	Treatment of hypertransaminasemia

Publications (1)

Publication Number	Publication Date
GB201412010D0 true GB201412010D0 (en)	2014-08-20

Family

ID=51410691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
GBGB1412010.9A Ceased GB201412010D0 (en)	2014-07-04	2014-07-04	Treatment of hypertransaminasemia

Country Status (2)

Country	Link
GB (1)	GB201412010D0 (en)
WO (1)	WO2016001682A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2019510056A (en) *	2016-03-30	2019-04-11	サミット（オックスフォード）リミテッド	Composition for the treatment of Duchenne muscular dystrophy
CN109355389B (en) *	2018-11-28	2022-02-18	陕西中医药大学	B4GALNT2 gene as biomarker for liver cancer detection and application thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101426093B1 (en)	2006-02-10	2014-08-01	서미트 코포레이션 피엘씨	Treatment of duchenne muscular dystrophy
KR20090005296A (en)	2006-02-10	2009-01-13	서미트 코포레이션 피엘씨	Treatment of duchenne muscular dystrophy
WO2009013477A1 (en)	2007-07-23	2009-01-29	Summit Corporation Plc	Compounds for treating duchenne muscular dystrophy
ES2617957T3 (en)	2007-08-03	2017-06-20	Summit (Oxford) Limited	Pharmacological combinations for the treatment of Duchenne muscular dystrophy
GB0715937D0 (en)	2007-08-15	2007-09-26	Vastox Plc	Method of treatment og duchenne muscular dystrophy
GB0715938D0 (en)	2007-08-15	2007-09-26	Vastox Plc	Method of treatment of duchenne muscular dystrophy
GB0715939D0 (en)	2007-08-15	2007-09-26	Vastox Plc	Method of treatment of duchenne muscular dystrophy
JP2011516442A (en)	2008-04-04	2011-05-26	ビオマリンアイジーエーリミテッド	Compounds for treating muscular dystrophy
GB0809314D0 (en)	2008-05-22	2008-07-02	Summit Corp Plc	Compounds for treating muscular dystrophy
GB0815369D0 (en)	2008-08-22	2008-10-01	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en)	2008-11-21	2008-12-31	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en)	2008-12-17	2009-01-21	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
WO2010086040A1 (en)	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
GB0905670D0 (en)	2009-04-02	2009-05-20	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
GB0905667D0 (en)	2009-04-02	2009-05-20	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
GB0905664D0 (en)	2009-04-02	2009-05-13	Summit Corp Plc	Compounds for treatment of duchenne muscular dystrophy
GB201208178D0 (en)	2012-05-10	2012-06-20	Summit Corp Plc	Pharmaceutical composition for the treatment of duchenne muscular dystrophy

2014
- 2014-07-04 GB GBGB1412010.9A patent/GB201412010D0/en not_active Ceased
2015
- 2015-07-02 WO PCT/GB2015/051943 patent/WO2016001682A1/en active Application Filing

Also Published As

Publication number	Publication date
WO2016001682A1 (en)	2016-01-07

Legal Events

Date	Code	Title	Description
2015-12-30	AT	Applications terminated before publication under section 16(1)

Publication	Publication Date	Title
IL252839A0 (en)	2017-08-31	Treatment of pemphigus
GB201701673D0 (en)	2017-03-15	Methods of well treatment
FI3851537T3 (en)	2024-03-21	Treatment of hyperbilirubinemia
IL248856A0 (en)	2017-01-31	New treatment
SG11201609652RA (en)	2016-12-29	Treatment of polybacterials infections
HK1244711A1 (en)	2018-08-17	Treatment of hmgb1-mediated inflammation
GB201410116D0 (en)	2014-07-23	Method of treatment
GB201416832D0 (en)	2014-11-05	Methods of treatment
IL253028A0 (en)	2017-08-31	Method of treatment
IL246880A0 (en)	2016-08-31	Treatment of neoplasia
GB201408297D0 (en)	2014-06-25	Treatment of cancer
GB201412010D0 (en)	2014-08-20	Treatment of hypertransaminasemia
GB201411027D0 (en)	2014-08-06	Treatment
GB201512139D0 (en)	2015-08-19	Methods of treatment
GB201417456D0 (en)	2014-11-19	Treatment of cancer
ZA201504639B (en)	2016-05-25	Treatment of water
PT3851537T (en)	2024-03-06	Treatment of hyperbilirubinemia
GB201421982D0 (en)	2015-01-21	Method of treatment
GB201421980D0 (en)	2015-01-21	Method of treatment
GB201415331D0 (en)	2014-10-15	Method of treatment
GB201414780D0 (en)	2014-10-01	Method Of Treatment
GB201413317D0 (en)	2014-09-10	Atheroscierosis treatment
GB201417719D0 (en)	2014-11-19	New treatment
GB201412411D0 (en)	2014-08-27	Treatment
GB201412410D0 (en)	2014-08-27	Treatment